title: Mannan-binding lectin deficiency - Good news, bad news, doesn't matter?
abstract: Mannan-binding lectin (MBL) deficiency has been classified as a commonly occurring immune disorder, affecting approximately 30% of the human population. MBL, being part of the innate immune system, supports the recognition of infectious pathogens by binding to carbohydrate moieties expressed on microorganisms and activates the lectin pathway of the complement system. MBL2 gene polymorphisms are associated with quantitative and qualitative MBL abnormalities in the serum. The clinical impact of MBL deficiency and its association to a wide variety of diseases has been extensively studied. The picture is puzzling as the studies suggest a detrimental or beneficial or no impact of low or high MBL serum levels on disease susceptibility. In this review we attempt to extract what is relevant from the literature and address controversial issues. We finally suggest that a comprehensive understanding of the role of MBL in human diseases requires considering its context-dependency.
authors.affiliation: Children's Cancer Research Institute, Vienna, Austria.
authors.forename: Sabine
authors.initials: S
authors.lastname: Heitzeneder
authors.forename: Markus
authors.initials: M
authors.lastname: Seidel
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Förster-Waldl
authors.forename: Andreas
authors.initials: A
authors.lastname: Heitger
mesh_terms: D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D037601:Mannose-Binding Lectin / Q000097:blood / Q000172:deficiency* / Q000235:genetics*; D008957:Models, Genetic; D020641:Polymorphism, Single Nucleotide
chemical_list: C445619:MBL2 protein, human; D037601:Mannose-Binding Lectin